TipRanks
BioAge Labs, Inc. (BIOA)
NASDAQ:BIOA
US Market
BIOA
BioAge Labs, Inc.
RESEARCH TOOLSreports
Want to see BIOA full AI Analyst Report?

BioAge Labs, Inc. (BIOA) Stock Forecast & Price Target

159 Followers
See the Price Targets and Ratings of:

BIOA Analyst Ratings

Moderate Buy
10Ratings
Moderate Buy
7 Buy
3 Hold
0 Sell
Based on 10 analysts giving stock ratings to
BioAge
Labs, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BIOA Stock 12 Month Forecast

Average Price Target

$32.56
▲(222.01% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for BioAge Labs, Inc. in the last 3 months. The average price target is $32.56 with a high forecast of $73.00 and a low forecast of $8.00. The average price target represents a 222.01% change from the last price of $10.11.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","39":"$39","74":"$74","21.5":"$21.5","56.5":"$56.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":73,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$73.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.55555555555556,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,21.5,39,56.5,74],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.81,11.901538461538461,16.993076923076924,22.084615384615383,27.176153846153845,32.26769230769231,37.35923076923077,42.45076923076923,47.542307692307695,52.63384615384616,57.72538461538462,62.81692307692308,67.90846153846154,{"y":73,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.81,8.79042735042735,10.7708547008547,12.75128205128205,14.731709401709402,16.712136752136754,18.692564102564102,20.672991452991454,22.653418803418806,24.633846153846154,26.614273504273505,28.594700854700857,30.575128205128205,{"y":32.55555555555556,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.81,6.901538461538461,6.993076923076923,7.084615384615384,7.176153846153846,7.2676923076923075,7.359230769230769,7.450769230769231,7.542307692307692,7.633846153846154,7.725384615384615,7.816923076923077,7.908461538461538,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.92,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.93,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.23,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.1,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.71,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.73,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.79,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.26,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.04,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.52,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.81,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$73.00Average Price Target$32.56Lowest Price Target$8.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on BIOA
Samantha Semenkow
Citi
Citi
$21
Buy
107.72%
Upside
Reiterated
10/14/26
BioAge Maintained at Buy as AI-Driven Discovery and Partnerships Support Growth; $21 Price Target Reaffirmed
UBS Analyst forecast on BIOA
Alice Nettleton
UBS
UBS
$8
Hold
-20.87%
Downside
Initiated
10/12/26
BioAge Labs, Inc. (BIOA) Has a New Rating from UBS
Needham Analyst forecast on BIOA
Joseph Stringer
Needham
Needham
$35
Buy
246.19%
Upside
Reiterated
09/14/26
Analysts Offer Insights on NA Companies: Fair Isaac (NYSE: FICO), Freeport-McMoRan (NYSE: FCX) and BioAge Labs, Inc. (NASDAQ: BIOA)
Roth MKM Analyst forecast on BIOA
Adam Walsh
Roth MKM
Roth MKM
$25
Buy
147.28%
Upside
Reiterated
09/09/26
Analysts' Top NA Picks: BioAge Labs, Inc. (BIOA), OS Therapies Incorporated (OSTX)
Morgan Stanley Analyst forecast on BIOA
Michael Ulz
Morgan Stanley
Morgan Stanley
$23→$20
Hold
97.82%
Upside
Reiterated
08/07/26
BioAge Labs price target lowered to $20 from $23 at Morgan StanleyBioAge Labs price target lowered to $20 from $23 at Morgan Stanley
Oppenheimer Analyst forecast on BIOA
Jay Olson
Oppenheimer
Oppenheimer
$50
Buy
394.56%
Upside
Reiterated
08/06/26
Oppenheimer Sticks to Its Buy Rating for BioAge Labs, Inc. (BIOA)
Piper Sandler Analyst forecast on BIOA
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$73
Buy
622.06%
Upside
Assigned
08/06/26
BioAge Labs, Inc. (BIOA) Gets a Buy from Piper Sandler
William Blair Analyst forecast on BIOA
Andy Hsieh
William Blair
William Blair
―
Hold
―
Reiterated
08/06/26
Andy Hsieh Reiterates Hold on BioAge as Strong Cash Runway Offsets Execution and Clinical Surrogate Uncertainties
BTIG Analyst forecast on BIOA
Thomas Shrader
BTIG
BTIG
$40
Buy
295.65%
Upside
Reiterated
08/05/26
Shrader Reiterates Buy on BioAge, Citing Differentiated NLRP3 Strategy and Attractive Valuation with Unchanged $40 Price Target
Jefferies Analyst forecast on BIOA
Roger Song
Jefferies
Jefferies
$62→$21
Buy
107.72%
Upside
Reiterated
07/31/26
BioAge Therapeutics: Buy Rating Maintained Despite Cut in Price Target to $21 on Refined ASCVD and Ocular Program Assumptions
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on BIOA
Samantha Semenkow
Citi
Citi
$21
Buy
107.72%
Upside
Reiterated
10/14/26
BioAge Maintained at Buy as AI-Driven Discovery and Partnerships Support Growth; $21 Price Target Reaffirmed
UBS Analyst forecast on BIOA
Alice Nettleton
UBS
UBS
$8
Hold
-20.87%
Downside
Initiated
10/12/26
BioAge Labs, Inc. (BIOA) Has a New Rating from UBS
Needham Analyst forecast on BIOA
Joseph Stringer
Needham
Needham
$35
Buy
246.19%
Upside
Reiterated
09/14/26
Analysts Offer Insights on NA Companies: Fair Isaac (NYSE: FICO), Freeport-McMoRan (NYSE: FCX) and BioAge Labs, Inc. (NASDAQ: BIOA)
Roth MKM Analyst forecast on BIOA
Adam Walsh
Roth MKM
Roth MKM
$25
Buy
147.28%
Upside
Reiterated
09/09/26
Analysts' Top NA Picks: BioAge Labs, Inc. (BIOA), OS Therapies Incorporated (OSTX)
Morgan Stanley Analyst forecast on BIOA
Michael Ulz
Morgan Stanley
Morgan Stanley
$23→$20
Hold
97.82%
Upside
Reiterated
08/07/26
BioAge Labs price target lowered to $20 from $23 at Morgan StanleyBioAge Labs price target lowered to $20 from $23 at Morgan Stanley
Oppenheimer Analyst forecast on BIOA
Jay Olson
Oppenheimer
Oppenheimer
$50
Buy
394.56%
Upside
Reiterated
08/06/26
Oppenheimer Sticks to Its Buy Rating for BioAge Labs, Inc. (BIOA)
Piper Sandler Analyst forecast on BIOA
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$73
Buy
622.06%
Upside
Assigned
08/06/26
BioAge Labs, Inc. (BIOA) Gets a Buy from Piper Sandler
William Blair Analyst forecast on BIOA
Andy Hsieh
William Blair
William Blair
―
Hold
―
Reiterated
08/06/26
Andy Hsieh Reiterates Hold on BioAge as Strong Cash Runway Offsets Execution and Clinical Surrogate Uncertainties
BTIG Analyst forecast on BIOA
Thomas Shrader
BTIG
BTIG
$40
Buy
295.65%
Upside
Reiterated
08/05/26
Shrader Reiterates Buy on BioAge, Citing Differentiated NLRP3 Strategy and Attractive Valuation with Unchanged $40 Price Target
Jefferies Analyst forecast on BIOA
Roger Song
Jefferies
Jefferies
$62→$21
Buy
107.72%
Upside
Reiterated
07/31/26
BioAge Therapeutics: Buy Rating Maintained Despite Cut in Price Target to $21 on Refined ASCVD and Ocular Program Assumptions
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioAge Labs, Inc.

3 Months
Samantha SemenkowCiti
Success Rate
3/9 ratings generated profit
33%
Average Return
+1.39%
Copying Samantha Semenkow's trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of +1.39% per trade.
1 Year
Samantha SemenkowCiti
Success Rate
1/9 ratings generated profit
11%
Average Return
-45.40%
Copying Samantha Semenkow's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -45.40% per trade.
2 Years
Samantha SemenkowCiti
Success Rate
1/9 ratings generated profit
11%
Average Return
-45.40%
Copying Samantha Semenkow's trades and holding each position for 2 Years would result in 11.11% of your transactions generating a profit, with an average return of -45.40% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BIOA Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
6
9
13
15
11
Buy
0
0
0
0
0
Hold
4
5
5
4
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
14
18
19
14
In the current month, BIOA has received 11 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. BIOA average Analyst price target in the past 3 months is 32.56.
Each month's total comprises the sum of three months' worth of ratings.

BIOA Financial Forecast

BIOA Earnings Forecast

Next quarter’s earnings estimate for BIOA is -$0.64 with a range of -$0.87 to -$0.47. The previous quarter’s EPS was -$0.58. BIOA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year BIOA has Performed in-line its overall industry.
Next quarter’s earnings estimate for BIOA is -$0.64 with a range of -$0.87 to -$0.47. The previous quarter’s EPS was -$0.58. BIOA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year BIOA has Performed in-line its overall industry.

BIOA Sales Forecast

Next quarter’s sales forecast for BIOA is $1.48M with a range of $0.00 to $3.00M. The previous quarter’s sales results were $2.45M. BIOA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year BIOA has Performed in-line its overall industry.
Next quarter’s sales forecast for BIOA is $1.48M with a range of $0.00 to $3.00M. The previous quarter’s sales results were $2.45M. BIOA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year BIOA has Performed in-line its overall industry.

BIOA Stock Forecast FAQ

What is BIOA’s average 12-month price target, according to analysts?
Based on analyst ratings, BioAge Labs, Inc.’s 12-month average price target is 32.56.
    What is BIOA’s upside potential, based on the analysts’ average price target?
    BioAge Labs, Inc. has 222.01% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BIOA a Buy, Sell or Hold?
          BioAge Labs, Inc. has a consensus rating of Moderate Buy which is based on 7 buy ratings, 3 hold ratings and 0 sell ratings.
            What is BioAge Labs, Inc.’s price target?
            The average price target for BioAge Labs, Inc. is 32.56. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $73.00 ,the lowest forecast is $8.00. The average price target represents 222.01% Increase from the current price of $10.11.
              What do analysts say about BioAge Labs, Inc.?
              BioAge Labs, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of BIOA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.